Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow

by Zacks Equity Research

QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.

Zacks Equity Research

QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails

by Zacks Equity Research

The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.

Zacks Equity Research

QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen

by Zacks Equity Research

QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.

Zacks Equity Research

QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval

by Zacks Equity Research

QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.

Zacks Equity Research

QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification

by Zacks Equity Research

QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.

Zacks Equity Research

3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.

Zacks Equity Research

QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up

by Zacks Equity Research

The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).

Zacks Equity Research

Qiagen (QGEN) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 17.78% and 4.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.